1. Pfizer, which manufactures the EpiPen for Mylan, was sent a warning letter by the FDA over a failure to investigate reports of device malfunctions. The FDA said Pfizer received hundreds of complaints about EpiPens that didn’t deliver the proper dose of epinephrine. (NYT)
2. Bristol-Myers Squibb ended a clinical trial testing a combination of its immunotherapy Opdivo with Yervoy after the drugmaker found it improved survival rates for patients with kidney cancer compared to the standard of care. (Reuters)
3. Patients that discuss cancer costs with their oncologist often pay less for their care, according to a new study published in the Journal of Oncology Practice. (Reuters)
4. Opioid use may be responsible for a 20% decline in the participation of American men in the U.S. labor force, according to a new study. (Bloomberg)
5. ICYMI: Merck was one of the lead participants in a fundraising round for Antidote.me, a startup looking to improve clinical-trial recruitment. (CNBC)
